An Overview of what is likely to be a RECORD year for HHSE

New Post Public Reply Private Reply Replies (0) Message Board
kidzdmd
Quote:
An Overview of what is likely to be a RECORD year for HHSE / Medallion!
Greetings HHSE Friends & Followers. "The silence has been deafening," as reported to us by many shareholders. Why has the company refrained from P.R. Announcements, I.R. outreach, customary (scheduled) filings, as general communications?

The detailed answers would be voluminous. But the SHORT answer is: Establishment of Corporate Priorities (and a focus onto those areas of greatest immediate and long-term benefit to the Company).

In the past year, so many new opportunities have arisen, and so many market changes have occurred, that an evaluation of what is working best, and how to "do more of it" has become essential.

While handling the revisions and updates to the Company's Form 10 filing - and making the in-depth disclosures and managerial analyses required for a proper registration - one can take a high-altitude view of the business that the day-to-day distractions of managing a complex business can sometimes obfuscate. The patterns and data results that have emerged suggest that some of the Company's activities are less attractive than others - and by a significant degree.

For instance, two areas that are NOT meeting management's hopes are:

1). "Direct to DVD" Releases - the return-on-investment for low-end titles has fallen dramatically, as consumers are less willing to spend $9.96 on a no-name, non-theatrical horror video than in year's past. As the sales have declined, the cost-of-goods has stayed the same, as we have an obligation to keep the Walmart and Best Buy shelves well stocked (even for "slow" moving titles). This changing aspect of the market indicates that non-theatrical titles are less attractive now for HHSE / Medallion to release.

2). "Low-End" International Sales - After a highly visible presence this year at Cannes - including a booth, multiple full-page trade ads, and four official market screenings - we have concluded that the international market for "low-budget" / non-A-star features is insignificant. Most of the international licensors prefer to handle smaller films under "distribution deals" without paying an upfront licensing advance... and the only titles getting advances and big minimum guarantees are the higher-end, original productions. Accordingly, the benefit of handling and promoting smaller titles for the international market is dubious.

... and two areas that are EXCEEDING management's hopes are:

3). "Theatrical Services" - as major outlets (most notably NETFLIX and the PAY CABLE Networks) now REQUIRE some level of USA Theatrical release, the need for access to theatres has grown many-fold. Accordingly, the access that HHSE / Medallion have to secure screens at the top theatre chains nationwide has become a valuable commodity - and source of "theatrical servicing fees." This activity provides up-front payments to the Company - as opposed to prior business models in which the Company put up hundreds-of-thousands (or MILLIONS) of dollars in P&A Cash, Credit and Loans, only to have to wait YEARS for the revenue streams to pay it back (think back to the release of the movie "TWELVE" - and how painful that debt burden had been to the Company for the past five years). Additionally, we have found that MANY (if not MOST) of our paid, theatrical servicing clients have ALSO been engaging HHSE / Medallion to handle Home Video, Video on Demand and Television. So our access to theatres has become a strong acquisition tool as well as a source of operating cash flow... and the side benefit is that mass merchants and major video buyers (including REDBOX KIOSKS) have a strong preference towards carrying videos of films with theatrical momentum.

4). "Production Services" - As the worldwide film distribution market continued to mature in favor of bigger budgeted films, HHSE / Medallion have the challenge of trying to acquire rights to such titles. We have found that buying finished films on the festival circuit is a costly endeavor... with bidding wars against the Major Studios, the Weinsteins and Lionsgate often jacking prices to unprofitable levels. Instead, what we have found, is that facilitating the production of higher-end films is a smarter strategy for both controlling the distribution rights up-front... but also as a source of up-front "production services" fees for the Company. Mid-level productions such as "Shadow Vision", "True Freshman" and "The Final Minute" provide reasonable cash-flow for overhead and operations... while mega productions such as "Mother Goose" and "AJA" are structured even more lucratively for the Company. Having ownership of our own film gear and Grip Truck is another plus, as are the three State of Arkansas incentives for original productions (15% across the board; an additional 10% for Arkansas entities and residents; and additional 25% for technology positions and post-production under the EEDC).

So Parkinson, Shefte and Sims have been working to reorganize the DVD side to minimize costs and maximize efficiencies. As the Company has been very pleased with the consistent success that Cinedigm has achieved in placing two or three titles PER MONTH into Walmart and Best Buy (and sometimes into Target), we are looking for ways to increase profitability. Accordingly, over the next two months, HHSE new release DVD and BluRay fulfillment will be moved to Technicolor (Memphis) to save on freight, overhead and time efficiencies (and this is the warehouse facility where the Cinedigm distributed studios are shipped out from).

We are also looking at providing more managerial attention to both the Theatrical Servicing activities as well as to the Production Services.

We remain commited to our existing product lines, but want to provide greater attention and emphasis into those areas of greatest benefit. Below is a list of three titles already slated for Q4 theatrical release (there's another BIG title, a possible fourth Q4 theatrical release, but it's still in post-production at present and may not make it in time for Academy eligibility this year). Also below is a list of upcoming DVD and BluRay placements for Walmart (and other Mass Merchants), showing an ongoing commitment to the physical home video side of the business. Each of these titles is also being exploited day-and-date with home video onto Video-On-Demand Platforms, and 60-days later, the theatrical items will be available for subscription streaming through Netflix.

These managerial priorities impact the daily operations and affect the narrative of the Form 10 and business plan. But they are the reasons that the Company has been incredibly QUIET for several months. This is about to change, beginning Monday with a nice feature interview from Uptick Newswire and I-Heart Radio / as well as Investor's Hangout featured visibility. There will also be traditional Newswire press releases, and enhanced visibility from social media platforms and websites. The Q2 filings at long last will be released in the next few days, and as the Company feels prepared to provide information on the current status of the FORM 10 and the pre-build-up of features for VODWIZ, these will also be released (but not necessarily next week).

We are appreciative of the extreme patience that our LONGS have provided to the Company - and know that you have suffered for months under a cone of silence from the Company. We recognized that the Stock Price and Volume have suffered, and we hope that our ignition of outreach through information and disclosures will help reverse this currently low pricing status.

Hannover House Inc. (HHSE) Stock Research Links

HHSE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 189

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 85

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 129

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 389

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 0

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading

Top 5 Most Recently Viewed Articles

Vor Bio's Exploration of Strategic Alternatives for Growth

Updated Category News Views 213

Vor Bio Announces Exploration of Strategic Alternatives Today, Vor Bio, a clinical-stage cell and genome engineering company, has taken significant steps to enhance shareholder value. The decision comes at a time when the clinical data from its major programs suggests that reevaluating its approach could be beneficial in the face of challenging fundraising conditions....

Continue Reading
Kraig Biocraft Achieves Record Production in Spider Silk Fibers

Updated Category News Views 56

Kraig Biocraft Laboratories' Milestone in Spider Silk Production Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneering firm renowned for its innovative developments in spider silk-based fibers, is thrilled to share the successful conclusion of its fourth production cycle for the year. This cycle represents a remarkable achievement, showcasing record-breaking...

Continue Reading
Gen X Faces Retirement Challenges: Understanding the Crisis

Updated Category News Views 282

Gen X’s Coming Retirement Crunch Gen X—often called the “sandwich generation”—is being pulled in two directions at once and edging toward a retirement problem many don’t fully see. With money, time, and attention split between family and work, long-term savings can drift to the back burner. The worry isn’t abstract; it’s about whether the money will be...

Continue Reading
Luxurious Villa Spectre: A $55 Million Icon of Elegance

Updated Category News Views 342

Villa Spectre: A $55 Million Marvel of Luxury Living Villa Spectre has recently captured the spotlight as the highest-priced sale in the area, setting a remarkable benchmark in luxury real estate. This impressive estate was sold for $55,000,000, showcasing the allure and opulence that the elite have come to expect from high-end properties. A Visionary Creation Designed by...

Continue Reading
Mosaic Minerals Shifts Focus to Gold with Amanda Acquisition

Updated Category News Views 333

Mosaic Minerals Re-prioritizes Focus on Gold Exploration Mosaic Minerals Corporation (CSE: MOC) is making a strategic pivot in its exploration efforts. The company has announced the cessation of its lithium exploration initiatives, particularly those in Jamésie, Quebec. Instead, Mosaic is setting its sights on more promising ventures in gold and nickel, specifically...

Continue Reading